icotinib + dihydroartemisinin

Icotinib + dihydroartemisinin is a combination of two small molecule drugs with distinct mechanisms of action. Icotinib is a highly selective first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that binds reversibly to the ATP binding site of EGFR, blocking signal transduction and inhibiting cancer cell proliferation. It is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations[1][3][4]. Dihydroartemisinin (DHA), also known as artenimol, is an active metabolite of artemisinin derivatives widely used as an antimalarial agent and has demonstrated anticancer activity. Its mechanism involves Fe(II)-mediated cleavage of its endoperoxide bridge to generate cytotoxic free radicals that induce apoptosis in tumor cells[2][6]. The combination leverages complementary mechanisms—targeted inhibition of oncogenic signaling by icotinib and oxidative damage by DHA—to potentially enhance anticancer efficacy.

Other names

artenimolDHA